JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

Search

United Therapeutics Corp

Geschlossen

BrancheGesundheitswesen

482.4 0.93

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

472.51

Max

485.42

Schlüsselkennzahlen

By Trading Economics

Einkommen

29M

339M

Verkäufe

900K

800M

KGV

Branchendurchschnitt

18.006

84.243

Gewinnspanne

42.364

Angestellte

1,305

EBITDA

26M

463M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+16.88% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

25. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.7B

21B

Vorheriger Eröffnungskurs

481.47

Vorheriger Schlusskurs

482.4

Nachrichtenstimmung

By Acuity

18%

82%

32 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

United Therapeutics Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Feb. 2026, 23:11 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3. Feb. 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Feb. 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3. Feb. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3. Feb. 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3. Feb. 2026, 23:38 UTC

Ergebnisse

AMD Sales Climb on Help From Data-Center Business -- Update

3. Feb. 2026, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3. Feb. 2026, 23:27 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3. Feb. 2026, 23:25 UTC

Akquisitionen, Fusionen, Übernahmen

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3. Feb. 2026, 23:23 UTC

Akquisitionen, Fusionen, Übernahmen

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3. Feb. 2026, 23:22 UTC

Akquisitionen, Fusionen, Übernahmen

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3. Feb. 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3. Feb. 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Feb. 2026, 22:56 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3. Feb. 2026, 22:40 UTC

Ergebnisse

Amdocs Extends Collaboration With T-Mobile

3. Feb. 2026, 22:39 UTC

Ergebnisse

Amdocs 1Q Adj EPS $1.81

3. Feb. 2026, 22:39 UTC

Ergebnisse

Amdocs 1Q Rev $1.16B

3. Feb. 2026, 22:39 UTC

Ergebnisse

Amdocs 1Q EPS $1.45 >

3. Feb. 2026, 22:38 UTC

Ergebnisse

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3. Feb. 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3. Feb. 2026, 22:14 UTC

Ergebnisse

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3. Feb. 2026, 22:13 UTC

Ergebnisse

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3. Feb. 2026, 22:12 UTC

Ergebnisse

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3. Feb. 2026, 22:10 UTC

Ergebnisse

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3. Feb. 2026, 22:10 UTC

Ergebnisse

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3. Feb. 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3. Feb. 2026, 22:10 UTC

Ergebnisse

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3. Feb. 2026, 22:09 UTC

Ergebnisse

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3. Feb. 2026, 22:09 UTC

Ergebnisse

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer-Vergleich

Kursveränderung

United Therapeutics Corp Prognose

Kursziel

By TipRanks

16.88% Vorteil

12-Monats-Prognose

Durchschnitt 555.2 USD  16.88%

Hoch 645 USD

Tief 423 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für United Therapeutics Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

4

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

292.345 / 309.245Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

32 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat